Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: Defining rejection patterns

被引:69
作者
Kfoury, Abdallah G.
Stehlik, Josef
Renlund, Dale G.
Snow, Gregory
Seaman, James T.
Gilbert, Edward M.
Stringham, James S.
Long, James W.
Hammond, M. Elizabeth H.
机构
[1] Latter Day St Hosp, Intermt Hlth Care, Salt Lake City, UT 84143 USA
[2] Univ Utah, Sch Med, Salt Lake City, UT USA
[3] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA
[4] Utah Transplant Affiliated Hosp, Cardiac Transplant Program, Salt Lake City, UT USA
关键词
D O I
10.1016/j.healun.2006.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In our previously published work dealing with antibody-mediated (vascular) rejection (AMR), we defined patterns of rejection (AMR and cellular rejection [CR]) based on a review of biopsy diagnoses taken in the first 6 to 12 weeks post-transplant. We have shown the significance of these pattern designations in relation to patient and allograft outcome in five outcome analyses. The current retrospective analysis was done to determine whether our previous criteria for pattern designations provided the greatest degree of discrimination between AMR and CR. Methods: Six hundred sixty-five patients from the U.T.A.H. Cardiac Transplant Program were included in our study. Patients induced with OKT3 immunosuppression were excluded. We analyzed the relationship of a number of either AMR or CR episodes to cardiovascular mortality. We constructed Kaplan-Meier survival curves to assess the impact of incremental numbers of AMR or CR episodes on cardiovascular mortality. Results: Three or more episodes of AMR resulted in a statistically significant increase in cardiovascular mortality. By contrast, CR episodes did not increase the risk of cardiovascular mortality. Conclusions: Based on our findings, we believe that clinical trials should be designed to test treatments based on predominant rejection patterns and that end-points for trials should be defined by number of biopsies positive for either CR or AMR. This approach may lead to improved patient and allograft survival.
引用
收藏
页码:1277 / 1282
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2006, a language and environment for statistical computing
[2]   Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes [J].
Baldwin, WM ;
Samaniego-Picota, M ;
Kasper, EK ;
Clark, AM ;
Czader, M ;
Rohde, C ;
Zachary, AA ;
Sanfilippo, F ;
Hruban, RH .
TRANSPLANTATION, 1999, 68 (06) :894-900
[3]   Complement as a mediator of vascular inflammation and activation in allografts [J].
Baldwin, WM ;
Qian, ZP ;
Ota, H ;
Samaniego, M ;
Wasowska, B ;
Sanfilippo, F ;
Hruban, RH .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (08) :723-730
[4]  
Billingham M E, 1990, J Heart Transplant, V9, P587
[5]  
BONNAUD EN, 1995, J HEART LUNG TRANSPL, V14, P163
[6]   Optimizing the immunosuppressive regimen in heart transplantation [J].
Eisen, H ;
Ross, H .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (05) :S207-S213
[7]  
ENSLEY RD, 1991, TRANSPLANT P, V23, P1130
[8]  
HAMMOND EH, 1989, J HEART TRANSPLANT, V8, P430
[9]  
HAMMOND EH, 1992, J HEART LUNG TRANSPL, V11, P111
[10]   Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: A study of 3,170 biopsies [J].
Hammond, MEH ;
Stehlik, J ;
Snow, G ;
Renlund, DG ;
Seaman, J ;
Dabbas, B ;
Gilbert, EM ;
Stringham, JC ;
Long, JW ;
Kfoury, AG .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (12) :2015-2021